Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation12

Autor: Lawen, Joseph G., Davies, Elizabeth A., Mourad, Georges, Oppenheimer, Frederic, Molina, Miguel Gonzalez, Rostaing, Lionel, Wilkinson, Alan H., Mulloy, Laura L., Bourbigot, Bernard J., Prestele, Hans, Korn, Alexander, Girault, Danièle
Zdroj: Transplantation; January 2003, Vol. 75 Issue: 1 p37-43, 7p
Abstrakt: Acute rejection remains a major problem in renal transplantation. Immunoprophylaxis with basiliximab (Simulect) has achieved significant reductions in acute rejection episodes in renal allograft recipients receiving dual immunosuppression. This study explored the tolerability and cumulative benefit of combining basiliximab with triple-drug therapy—cyclosporine (USP Modified, Neoral), mycophenolate mofetil, and steroids.
Databáze: Supplemental Index